

RECEIVED
CENTRAL FAX CENTER

MAY 17 2005



ATTORNEYS AT LAW

8TH FLOOR
1100 NORTH GLEBE ROAD
ARLINGTON, VIRGINIA 22201-4714TELEPHONE: (703) 816-4000
FACSIMILE: (703) 816-4100
WRITER'S DIRECT DIAL NUMBER:
(703) 816-4091**FACSIMILE COVER SHEET**
PLEASE DELIVER IMMEDIATELY!!!!Our Ref.: 2551-106
Your Ref.: Appln No. 09/851,138 Date: May 17, 2005To: Examiner Li
Firm: USPTO - Group 1648
Facsimile No.: Facsimile No.: 7038729306
(Courtesy Copy to Examiner's Fax No.: 5712730904)
From: B. J. SadoffNumber of Pages (including cover sheet): 10
(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION,
PLEASE CONTACT US IMMEDIATELY AT (703-816-4000).)**CERTIFICATION OF FACSIMILE TRANSMISSION**I hereby certify that this paper and any noted attachments are being facsimile transmitted to the Patent and
Trademark Office on May 17, 2005.B. J. Sadoff
Reg. No. 36663**INFORMATION DISCLOSURE STATEMENT**
EXPEDITED HANDLING PROCEDURESATTACHMENT/S: Information Disclosure Statement, copy of cited document, Credit Card Payment
Form (separate Courtesy Copy forwarded to Examiner by facsimile to 5712730904).

An extension fee for consideration and entry of this IDS should not be required as the applicants responded to the final
Office Action of January 11, 2005 within two months of the mailing date (i.e., on February 9, 2005) of the final Office Action
and an Advisory Action has not been mailed, it now being after the three month shortened statutory period from the mailing of
the final Office Action, such that the shortened statutory period has still not expired. See, page 3 of the Office Action dated
January 11, 2005.

In re Patent Application of MAERTENS, et al. Atty. Ref.: 2551-106			
Serial No.	09/851,138	Group:	1648
Filed:	May 9, 2001	Examiner:	Li
For:	SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTS		

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally
privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU
ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE
WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for
return of the original documents to us.

955534

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

MAY 17 2005

In re Patent Application of

MAERTENS, et al.

Atty. Ref.: 2551-106

Serial No. 09/851,138

Group: 1648

Filed: May 9, 2001

Examiner: Li

For: SEQUENCES OF HEPATITIS C VIRUS GENOTYPES
AND THEIR USE AS PROPHYLACTIC, THERAPEUTIC
AND DIAGNOSTIC AGENTS

* * * * *

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

May 17, 2005

Via facsimile (7038729306)

Courtesy Copy to Examiner facsimile
(571-273-0904)

Sir:

INFORMATION DISCLOSURE STATEMENT

☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C

☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C

☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00

☒ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

180.00 Op

955528

MAERTENS, et al.
Serial No. 09/851,138

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☒ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and and Rule 17(p) fee), but before final fee payment]; and
- ☒ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith as attached Credit Card Payment Form; and
- ☒ b) The required Statement is stated in item 8 below.
- ☒ 8. Statement under 37 CFR 1.97(e)
- ☒ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from the Japanese Patent Office in a counterpart foreign application on April 12, 2005, i.e., not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information

MAERTENS, et al.
Serial No. 09/851,138

Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

955528